The filing positions one of 2017’s star performers on European exchanges to start trading in the U.S. and fund a phase 3 pancreatic cancer trial.
Allena arrives on Wall Street armed with data from two phase 2 flops and a pivotal trial design that has so far failed to win over the FDA.
In life sciences companies, collaboration is key. It’s important for operational leaders to partner with finance leaders to consider risks and issues that may…
PanOptica plans to start trialling the small molecule anti-vascular endothelial growth factor eye drop early next year.
The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
A report from CNBC says that PayPal founder Peter Thiel and Facebook investor Sean Parker are investing in a new, secretive oncology biotech company.
Massachusetts startup Palleon Pharmaceuticals has raised $47.6 million to fund the development of cancer drugs that target sugar-sensing molecules.
Immatics turned to existing investors and new partner Amgen to put together the round, which brings its total raised to date up toward €200 million.
Ablynx is gearing up to commercialize the anti-von Willebrand factor single-domain antibody in the U.S. and Europe.
The idea is to manage the risks inherent in R&D by placing bets on eight to 10 early-stage assets and selling those that show promise in the clinic.
Vivek Ramaswamy’s Roivant has just put another sizable block of cash behind a hepatitis B program in development at Canada’s Arbutus Biopharma.